Antibacterial Drugs: World Market Prospects 2013-2023

Antibacterial Drugs: World Market Prospects 2013-2023

Report Details

Discover new trends, opportunities and revenue prospects for bacteria-killing medicines
Where's the antibiotics market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities.


Our study lets you assess sales data and predictions for the world antibacterial drugs market, therapeutic submarkets, important products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.

Established and emerging bacteria-treating technologies have potential. Read on to scan features of that industry, find what drives it, and see what its future market could be worth.

Forecasts and other analyses to help you stay ahead in knowledge

That report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developmental trends (R&D). You gain 113 tables, 86 charts and two research interviews.

Is finding commercial data a challenge? With our study you can stay ahead in knowledge, benefiting your research, analyses and decisions. There you find trends, innovations and opportunities for human medicine. You see what's happening, discovering possibilities.

There is rising need worldwide for drugs to treat bacterial infections. For those agents, our work helps you find business areas that will prosper, reducing the risk of your missing out.

The following sections show how you benefit from our new study of that antimicrobials field.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market for treating bacterial infections in human beings, you see forecasts to 2023 for these six submarkets:
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Other agents.

Our work shows you overall commercial prospects for generic and novel antibiotics.

Do you understand the changing market, knowledge needed to achieve maximum sales? Our report helps you identify potential and find opportunities for your business to prosper.

Likewise, our investigation discusses what stimulates and restrains business. In that work you find dynamics of the industry and assess its potential sales, seeing what drugs are likely to achieve the most success.

See revenue forecasts for 26 leading drugs

How will leading antibiotics perform to 2023 at world level? Our study forecasts sales of 26 products, including these brands:
• Augmentin
• Zyvox
• Avelox
• Cubicin
• Zosyn
• Cravit/Levaquin
• Merrem/Meropen
• Biaxin/Clarith
• Primaxin.

There you discover how high sales can go, to 2023, finding areas and years with highest predicted revenues and growth. Also, find how competitors compare - assess competition. You see what's happening, understanding trends, challenges and opportunities.

That study also divides its overall world revenue forecast into those for the main geographical markets.

What prospects for leading regions and countries?

In developed and developing countries - especially India and China - there are still many opportunities for developing, manufacturing and selling drugs to treat bacterial infections. You see opportunities for producers and sellers of those antimicrobial medicines.

Our analyses show you individual revenue forecasts to 2023 for eleven national markets and one regional block:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5) and a forecast for the EU
• Brazil, Russia, India and China (BRIC).

There you discover progress and outlooks. That way you assess the industry's future - hear about developments and find their sig
Table of Contents

1. Executive Summary
1.1 Outlook for the Antibacterial Drugs Market 2013-2023
1.2 Report Contents
1.3 Research and Analysis Methods

2. An Introduction to Bacterial Infections and Antibacterial Drugs
2.1 Bacterial Infections
2.1.1 How Do Bacteria Cause Infections?
2.1.2 How Are Bacteria Classified?
2.1.3 Types of Bacterial Infection
2.1.4 Leading Causes of Bacterial Infection
2.1.5 Incidence and Mortality Patterns for Common Bacterial Infections
2.2 Treating Bacterial Infections
2.2.1 A Brief History of Antibacterial Drug Development
2.2.2 Antibacterial Drug Action
2.2.3 Leading Classes of Antibacterial Drug
2.2.3.1 Cephalosporins
2.2.3.2 Penicillins
2.2.3.3 Carbapenems
2.2.3.4 Fluoroquinolones
2.2.3.5 Macrolides
2.2.4 Antibacterial Drug Resistance

3. Outlook for the Antibacterial Drugs Market 2013-2023
3.1 The World Antibacterial Drugs Market 2011-2012
3.1.1 Steady Revenue Growth for Antibacterial Drugs 2009-2012
3.1.2 What Are the Leading Sectors of the Market?
3.2 The World Antibacterial Drugs Market Forecast 2013-2023
3.2.1 What Will Drive Market Growth 2013-2023?
3.2.2 Drug Resistance and Generics to Restrain Growth to 2023
3.2.3 Changes to Submarket Shares 2013-2023
3.3 Leading Antibacterial Manufacturers 2013
3.3.1 Antibacterial Drugs is a Highly Fragmented Market
3.3.2 Limited Pipelines for Market Leaders
3.3.3 Outlook for the Top Ten Antibacterial Manufacturers 2013-2023

4. The Cephalosporin Submarket 2013-2023
4.1 The Cephalosporin Submarket 2011-2012
4.1.1 Most Cephalosporins Have Lost Patent Protection
4.2 The Cephalosporin Submarket Forecast 2013-2023
4.2.1 What Will Drive and Restrain Growth in the Cephalosporins Submarket?
4.2.2 Zinforo (Ceftaroline): The Newest Cephalosporin
4.2.3 Many Cephalosporins in the Pipeline
4.3 Rocephin
4.3.1 Opportunities for Continued Revenue
4.3.2 Revenue Forecast 2013-2023
4.4 Zinnat
4.4.1 Revenue Forecast 2013-2023
4.5 Flomox: Japan's Leading Cephalosporin
4.5.1 Patent Challenges 2009-2011
4.5.2 Revenue Forecast 2013-2023
4.6 Sulperazon
4.6.1 Revenue Growth in Emerging Markets 2013-2023
4.7 Meiact is a Popular Cephalosporin in Japan
4.7.1 Cefditoren in the US
4.7.2 Revenue Forecast 2013-2023

5. The Penicillin Submarket 2013-2023
5.1 The Penicillin Submarket 2011-2012
5.2 Steady Growth for the Penicillin Submarket 2013-2023
5.2.1 Submarket Drivers and Restraints 2013-2023
5.3 Augmentin: Off-Patent Blockbuster Revenues for a Decade
5.3.1 Augmentin Revenue Continues to Fall
5.3.2 Augmentin Recalled in Asian and Middle Eastern Markets 2011-2012
5.3.3 Faster Revenue Decline for Augmentin to 2023
5.4 Zosyn: An Effective Pneumonia Therapy
5.4.1 Zosyn Revenue: Rising in Japan, but Falling in the US
5.4.2 Patent Expiry and Revenue Extension for Pfizer
5.4.3 Revenue Forecast 2013-2023
5.5 Unasyn
5.5.1 Revenue Forecast 2013-2023

6. The Fluoroquinolone Submarket 2013-2023
6.1 Declining Revenue for Fluoroquinolones 2011-2012
6.1.1 Safety Concerns with Fluoroquinolones
6.2 The Fluoroquinolone Submarket Forecast 2013-2023
6.2.1 Avelox Patent Expiries to Restrain Growth
6.2.2 Fluoroquinolone Pipeline 2013
6.2.3 Fluoroquinolones as Inhaled Antibiotics
6.3 Avelox
6.3.1 Safety Concerns Affecting Revenue?
6.3.2 Patent Challenges
6.3.3 Will Avelox Remain as the Leading Fluoroquinolone to 2023?
6.4 Vigamox
6.4.1 Branded and Generic Challenges 2009-2012
6.4.2 Moxeza: A Next-Generation Form of Vigamox
6.4.3 Declining Revenue 2013-2023
6.5 Cravit and Levaquin
6.5.1 Generic Competition Affecting Revenue Worldwide
6.5.2 Lifecycle Management for Cravit and Levaquin
6.5.3 Continued Fall in Revenue 2013-2023
6.6 Cipro and Ciprodex: Two Formulations of Ciprofloxacin<